U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Spherocytosis

MedGen UID:
154301
Concept ID:
C0553720
Finding; Finding
SNOMED CT: Spherocytosis (17235000)
 
HPO: HP:0004444

Definition

The presence of erythrocytes that are sphere-shaped. [from HPO]

Conditions with this feature

Hereditary spherocytosis type 1
MedGen UID:
382302
Concept ID:
C2674218
Disease or Syndrome
Any hereditary spherocytosis in which the cause of the disease is a mutation in the ANK1 gene.
Hereditary spherocytosis type 2
MedGen UID:
436112
Concept ID:
C2674219
Disease or Syndrome
People with the mild form may have very mild anemia or sometimes have no symptoms. People with the moderate form typically have anemia, jaundice, and splenomegaly. Many also develop gallstones. The signs and symptoms of moderate hereditary spherocytosis usually appear in childhood. Individuals with the moderate/severe form have all the features of the moderate form but also have severe anemia. Those with the severe form have life-threatening anemia that requires frequent blood transfusions to replenish their red blood cell supply. They also have severe splenomegaly, jaundice, and a high risk for developing gallstones. Some individuals with the severe form have short stature, delayed sexual development, and skeletal abnormalities.\n\nThere are four forms of hereditary spherocytosis, which are distinguished by the severity of signs and symptoms. They are known as the mild form, the moderate form, the moderate/severe form, and the severe form. It is estimated that 20 to 30 percent of people with hereditary spherocytosis have the mild form, 60 to 70 percent have the moderate form, 10 percent have the moderate/severe form, and 3 to 5 percent have the severe form.\n\nHereditary spherocytosis is a condition that affects red blood cells. People with this condition typically experience a shortage of red blood cells (anemia), yellowing of the eyes and skin (jaundice), and an enlarged spleen (splenomegaly). Most newborns with hereditary spherocytosis have severe anemia, although it improves after the first year of life. Splenomegaly can occur anytime from early childhood to adulthood. About half of affected individuals develop hard deposits in the gallbladder called gallstones, which typically occur from late childhood to mid-adulthood.
Hereditary spherocytosis type 5
MedGen UID:
436371
Concept ID:
C2675192
Disease or Syndrome
EPB42-related hereditary spherocytosis (EPB42-HS) is a chronic nonimmune hemolytic anemia that is usually of mild-to-moderate severity. EPB42-HS can present with jaundice as early as the first 24 hours of life or can present later in childhood with anemia resulting from a hemolytic crisis or aplastic crisis (usually associated with a viral infection). In addition to the hematologic manifestations, serious complications include splenomegaly, which can become evident in early childhood, and cholelithiasis, which usually becomes evident in the second or third decade of life. Typical laboratory findings in EPB42-HS include anemia (decreased hemoglobin [Hgb] level) and reticulocytosis (increased percentage of reticulocytes), with high mean corpuscular Hgb concentration, presence of spherocytes in the peripheral blood smear, significantly decreased or absent haptoglobin, mildly increased osmotic fragility in osmotic fragility assay, increased Omin (osmolality at which 50% of red blood cells hemolyze), and decreased maximal elongation index (EImax) in osmotic gradient ektacytometry.
Hereditary spherocytosis type 4
MedGen UID:
436375
Concept ID:
C2675212
Disease or Syndrome
People with the mild form may have very mild anemia or sometimes have no symptoms. People with the moderate form typically have anemia, jaundice, and splenomegaly. Many also develop gallstones. The signs and symptoms of moderate hereditary spherocytosis usually appear in childhood. Individuals with the moderate/severe form have all the features of the moderate form but also have severe anemia. Those with the severe form have life-threatening anemia that requires frequent blood transfusions to replenish their red blood cell supply. They also have severe splenomegaly, jaundice, and a high risk for developing gallstones. Some individuals with the severe form have short stature, delayed sexual development, and skeletal abnormalities.\n\nThere are four forms of hereditary spherocytosis, which are distinguished by the severity of signs and symptoms. They are known as the mild form, the moderate form, the moderate/severe form, and the severe form. It is estimated that 20 to 30 percent of people with hereditary spherocytosis have the mild form, 60 to 70 percent have the moderate form, 10 percent have the moderate/severe form, and 3 to 5 percent have the severe form.\n\nHereditary spherocytosis is a condition that affects red blood cells. People with this condition typically experience a shortage of red blood cells (anemia), yellowing of the eyes and skin (jaundice), and an enlarged spleen (splenomegaly). Most newborns with hereditary spherocytosis have severe anemia, although it improves after the first year of life. Splenomegaly can occur anytime from early childhood to adulthood. About half of affected individuals develop hard deposits in the gallbladder called gallstones, which typically occur from late childhood to mid-adulthood.
Hereditary spherocytosis type 3
MedGen UID:
394798
Concept ID:
C2678338
Disease or Syndrome
Hereditary spherocytosis is a condition that affects red blood cells. People with this condition typically experience a shortage of red blood cells (anemia), yellowing of the eyes and skin (jaundice), and an enlarged spleen (splenomegaly). Most newborns with hereditary spherocytosis have severe anemia, although it improves after the first year of life. Splenomegaly can occur anytime from early childhood to adulthood. About half of affected individuals develop hard deposits in the gallbladder called gallstones, which typically occur from late childhood to mid-adulthood.\n\nThere are four forms of hereditary spherocytosis, which are distinguished by the severity of signs and symptoms. They are known as the mild form, the moderate form, the moderate/severe form, and the severe form. It is estimated that 20 to 30 percent of people with hereditary spherocytosis have the mild form, 60 to 70 percent have the moderate form, 10 percent have the moderate/severe form, and 3 to 5 percent have the severe form.\n\nPeople with the mild form may have very mild anemia or sometimes have no symptoms. People with the moderate form typically have anemia, jaundice, and splenomegaly. Many also develop gallstones. The signs and symptoms of moderate hereditary spherocytosis usually appear in childhood. Individuals with the moderate/severe form have all the features of the moderate form but also have severe anemia. Those with the severe form have life-threatening anemia that requires frequent blood transfusions to replenish their red blood cell supply. They also have severe splenomegaly, jaundice, and a high risk for developing gallstones. Some individuals with the severe form have short stature, delayed sexual development, and skeletal abnormalities.

Professional guidelines

PubMed

Tole S, Dhir P, Pugi J, Drury LJ, Butchart S, Fantauzzi M, Langer JC, Baker JM, Blanchette VS, Kirby-Allen M, Carcao MD
Br J Haematol 2020 Nov;191(3):486-496. Epub 2020 May 20 doi: 10.1111/bjh.16750. PMID: 32436265
Manciu S, Matei E, Trandafir B
Chirurgia (Bucur) 2017 Mar-Apr;112(2):110-116. doi: 10.21614/chirurgia.112.2.110. PMID: 28463670
Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ; General Haematology Task Force of the British Committee for Standards in Haematology
Br J Haematol 2012 Jan;156(1):37-49. Epub 2011 Nov 5 doi: 10.1111/j.1365-2141.2011.08921.x. PMID: 22055020

Recent clinical studies

Etiology

Neamţu SD, Novac MB, Neamţu AV, Stanca ID, Boldeanu MV, Gluhovschi A, Stanca L, Dijmărescu AL, Manolea MM, Trăistaru MR, Mateescu GO, Siminel MA
Rom J Morphol Embryol 2022 Jan-Mar;63(1):229-235. doi: 10.47162/RJME.63.1.26. PMID: 36074689Free PMC Article
Tole S, Dhir P, Pugi J, Drury LJ, Butchart S, Fantauzzi M, Langer JC, Baker JM, Blanchette VS, Kirby-Allen M, Carcao MD
Br J Haematol 2020 Nov;191(3):486-496. Epub 2020 May 20 doi: 10.1111/bjh.16750. PMID: 32436265
Jamwal M, Sharma P, Das R
Indian J Pediatr 2020 Jan;87(1):66-74. Epub 2019 Dec 10 doi: 10.1007/s12098-019-03119-8. PMID: 31823208
Manciu S, Matei E, Trandafir B
Chirurgia (Bucur) 2017 Mar-Apr;112(2):110-116. doi: 10.21614/chirurgia.112.2.110. PMID: 28463670
Perrotta S, Gallagher PG, Mohandas N
Lancet 2008 Oct 18;372(9647):1411-26. doi: 10.1016/S0140-6736(08)61588-3. PMID: 18940465

Diagnosis

Wu Y, Liao L, Lin F
J Clin Lab Anal 2021 Dec;35(12):e24034. Epub 2021 Oct 24 doi: 10.1002/jcla.24034. PMID: 34689357Free PMC Article
Tole S, Dhir P, Pugi J, Drury LJ, Butchart S, Fantauzzi M, Langer JC, Baker JM, Blanchette VS, Kirby-Allen M, Carcao MD
Br J Haematol 2020 Nov;191(3):486-496. Epub 2020 May 20 doi: 10.1111/bjh.16750. PMID: 32436265
He BJ, Liao L, Deng ZF, Tao YF, Xu YC, Lin FQ
Acta Haematol 2018;139(1):60-66. Epub 2018 Jan 22 doi: 10.1159/000486229. PMID: 29402830
Manciu S, Matei E, Trandafir B
Chirurgia (Bucur) 2017 Mar-Apr;112(2):110-116. doi: 10.21614/chirurgia.112.2.110. PMID: 28463670
Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ; General Haematology Task Force of the British Committee for Standards in Haematology
Br J Haematol 2012 Jan;156(1):37-49. Epub 2011 Nov 5 doi: 10.1111/j.1365-2141.2011.08921.x. PMID: 22055020

Therapy

Liu Y, Jin S, Xu R, Ding C, Pang W, Li Y, Chen Y
Pediatr Res 2023 Apr;93(5):1336-1341. Epub 2022 Aug 1 doi: 10.1038/s41390-022-02229-y. PMID: 35915237
Iolascon A, Andolfo I, Barcellini W, Corcione F, Garçon L, De Franceschi L, Pignata C, Graziadei G, Pospisilova D, Rees DC, de Montalembert M, Rivella S, Gambale A, Russo R, Ribeiro L, Vives-Corrons J, Martinez PA, Kattamis A, Gulbis B, Cappellini MD, Roberts I, Tamary H; Working Study Group on Red Cells and Iron of the EHA
Haematologica 2017 Aug;102(8):1304-1313. Epub 2017 May 26 doi: 10.3324/haematol.2016.161166. PMID: 28550188Free PMC Article
Gallagher PG
Pediatr Clin North Am 2013 Dec;60(6):1349-62. Epub 2013 Oct 15 doi: 10.1016/j.pcl.2013.09.001. PMID: 24237975Free PMC Article
Huq S, Pietroni MA, Rahman H, Alam MT
J Health Popul Nutr 2010 Feb;28(1):107-9. doi: 10.3329/jhpn.v28i1.4529. PMID: 20214092Free PMC Article
Bowling MR, Cauthen CG, Perry CD, Patel NP, Bergman S, Link KM, Sane AC, Conforti JF
J Thorac Imaging 2008 May;23(2):138-41. doi: 10.1097/RTI.0b013e31815b89aa. PMID: 18520574

Prognosis

Yang L, Shu H, Zhou M, Gong Y
Clin Genet 2022 Dec;102(6):474-482. Epub 2022 Sep 26 doi: 10.1111/cge.14223. PMID: 36071563
Fonseca AC, Silva DP, Infante J, Ferro JM
Curr Neurol Neurosci Rep 2021 Sep 3;21(10):51. doi: 10.1007/s11910-021-01141-y. PMID: 34480226
Garzón G LN, Jaramillo B LE, Valero H JJ, Quintero C EM
J Pediatr Surg 2021 Mar;56(3):550-552. Epub 2020 Jun 3 doi: 10.1016/j.jpedsurg.2020.05.039. PMID: 32624207
Tole S, Dhir P, Pugi J, Drury LJ, Butchart S, Fantauzzi M, Langer JC, Baker JM, Blanchette VS, Kirby-Allen M, Carcao MD
Br J Haematol 2020 Nov;191(3):486-496. Epub 2020 May 20 doi: 10.1111/bjh.16750. PMID: 32436265
Jankulovski N, Antovic S, Kuzmanovska B, Mitevski A
Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2014;35(1):181-7. PMID: 24798604

Clinical prediction guides

Neamţu SD, Novac MB, Neamţu AV, Stanca ID, Boldeanu MV, Gluhovschi A, Stanca L, Dijmărescu AL, Manolea MM, Trăistaru MR, Mateescu GO, Siminel MA
Rom J Morphol Embryol 2022 Jan-Mar;63(1):229-235. doi: 10.47162/RJME.63.1.26. PMID: 36074689Free PMC Article
Yang L, Shu H, Zhou M, Gong Y
Clin Genet 2022 Dec;102(6):474-482. Epub 2022 Sep 26 doi: 10.1111/cge.14223. PMID: 36071563
Wu Y, Liao L, Lin F
J Clin Lab Anal 2021 Dec;35(12):e24034. Epub 2021 Oct 24 doi: 10.1002/jcla.24034. PMID: 34689357Free PMC Article
Tole S, Dhir P, Pugi J, Drury LJ, Butchart S, Fantauzzi M, Langer JC, Baker JM, Blanchette VS, Kirby-Allen M, Carcao MD
Br J Haematol 2020 Nov;191(3):486-496. Epub 2020 May 20 doi: 10.1111/bjh.16750. PMID: 32436265
Caimi G, Canino B, Lo Presti R, Urso C, Hopps E
Clin Hemorheol Microcirc 2017;67(1):25-34. doi: 10.3233/CH-160218. PMID: 28550239

Recent systematic reviews

Li J, Wang X, Zheng N, Wang X, Liu Y, Xue L
BMC Med Genomics 2022 Dec 3;15(1):250. doi: 10.1186/s12920-022-01399-2. PMID: 36463227Free PMC Article
Silva R, Amarasinghe D, Perera S, Premawardhena A
Int J Lab Hematol 2022 Apr;44(2):248-262. Epub 2022 Jan 23 doi: 10.1111/ijlh.13800. PMID: 35068068
Schizas D, Katsaros I, Karatza E, Kykalos S, Spartalis E, Tsourouflis G, Dimitroulis D, Nikiteas N
J Laparoendosc Adv Surg Tech A 2020 Jul;30(7):730-736. Epub 2020 Mar 23 doi: 10.1089/lap.2020.0004. PMID: 32202962
Liu G, Fan Y
World J Surg 2019 Jun;43(6):1505-1518. doi: 10.1007/s00268-019-04946-8. PMID: 30767061
Guizzetti L
Pediatr Blood Cancer 2016 Oct;63(10):1713-22. Epub 2016 Jun 14 doi: 10.1002/pbc.26106. PMID: 27300151

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...